NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-135-2019-0-SG-13 T CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN P53 SG National Stage 11202113949V Pending
NCATS E-046-2021-0-BR-01 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF BR National Stage BR2023011636-8 Pending
NIAID E-133-2015-0-US-11 NEUTRALIZING ANTIBODIES TO HIV-1 GP41 AND THEIR USE US CON 17/551,066 12043660 Issued PDF
NIAID E-007-2015-0-US-36 CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE US CON 17/550,881 11780931 Issued PDF
NCATS E-072-2022-1-US-01 MULTI-CYCLC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF US 63/289,341 Expired
NCI E-113-2021-0-US-01 BACTERIOPHAGE LAMBDA-VACCINE SYSTEM US 63/289,018 Expired
NCI E-147-2021-0-PCT-02 COMPOSITIONS AND METHODS FOR TREATING CANCER PCT PCT PCT/US2021/062832 Expired
NIAAA E-190-2021-0-US-01 Thiol-moeity Containing Cannabinoid Receptor Modulating Compounds US 63/265,225 Expired
NCI E-175-2016-0-JP-18 ANTI-KRAS-G12D T CELL RECEPTORS JP DIV 2021-199878 Issued
NINDS E-198-2021-0-PC-02 Therapeutics for the Treatment of Neurodegenerative Disorders PCT PCT PCT/EP2021/084908 Expired
NINDS E-071-2023-0-GB-01 Therapeutics for the Treatment of Neurodegenerative Disorders GB ORD 2117758.9 Pending
NIDA E-183-2021-0-US-01 PROTOCOL TO ENHANCE THERAPEUTIC EFFECTS OF TRANSCRANIAL MAGNETIC STIMULATION US 63/286,229 Expired
NIAID E-120-2001-1-AU-06 Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses AU DIV 2021282390 Expired
NCI E-175-2016-0-US-17 ANTI-KRAS-G12D T CELL RECEPTORS US CON 17/541,619 11840561 Issued PDF
NIAID E-052-2023-0-PC-01 COMBINATION THERAPY PCT PCT PCT/US2021/061697 Expired
NCATS E-212-2025-0-US-01 IRAK INHIBITORS COMBINATION THERAPIES US 63/285,663 Abandoned
NCI E-040-2012-0-JP-66 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen JP DIV 2021-196490 Issued
NCI E-190-2014-0-US-44 VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS US CON 17/540,549 12029794 Issued PDF
NCI E-181-2018-2-HK-05 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) HK EP 62021043492.9 Pending
NCI E-239-2017-0-BR-19 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS BR DIV BR122021024382-4 Pending
NCI E-219-2021-0-US-01 HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION US 63/284,884 Expired
NCI E-021-2015-0-AU-35 Anti-CD70 Chimeric Antigen Receptors AU DIV 2021277627 Issued
NCI E-285-2016-2-JP-07 Glypican 2 As A Cancer Marker And Therapeutic Target JP DIV 2021-194050 Issued
NCATS E-005-2022-0-US-01 THREE-DIMENSIONAL RESPIRATORY EPITHELIAL TISSUE CONSTRUCTS WITH PERFUSABLE MICROVASCULATURE ON A HIGH-THROUGHPUT MICROFLUIDICS SCREENING PLATFORM US 63/284,504 Expired
NCI E-199-2021-0-US-01 Ribosomal RNA Bait Oligonucleotide To Protect Against C9ORF72 ALS/FTD-associated Poly-GR Pathophysiology US 63/284,485 Expired
NIAID E-216-2021-0-US-03 Self-assembling Nanoparticles Based On Amphiphilic Peptides For Intravenous Drug Delivery US 63/284,375 Expired
NIAID E-208-2023-0-US-01 HUMAN METAPNEUMOVIRUS VIRAL VECTOR-BASED VACCINES US 63/284,407 Expired
NCI E-040-2022-0-PC-01 METHODS FOR TREATING BILE DUCT CANCERS WITH TIVOZANIB PCT PCT PCT/US2021/060902 Expired
NCI E-028-2022-0-US-01 METHODS FOR TREATING CANCERS WITH CYTOPLASMIC EXPORTIN 7 (XPO7) EXPRESSION WITH TIVOZANIB US 63/283,406 Abandoned
NCI E-028-2015-1-US-42 ANTI-MUTATED KRAS T CELL RECEPTORS US CON 17/535,318 12312391 Issued PDF
NEI E-089-2011-0-US-03 CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENT US CON 17/534,909 Abandoned
NCI E-080-2014-0-US-05 METHOD OF PREPARING ZIRCONIUM-89 OXINE COMPLEX US DIV 17/532,083 12473307 Issued PDF
NCI E-080-2014-0-US-06 ZIRCONIUM-89 OXINE COMPLEX AS A CELL LABELING AGENT FOR POSITRON EMISSION TOMOGRAPHY US CON 17/532,109 Pending
NIEHS E-241-2020-0-PCT-02 Massively Paralleled Multi-patient Assay For Pathogenic Infection Diagnosis And Host Physiology Surveillance Using Nucleic Acid Sequencing PCT PCT PCT/US21/59996 Expired
NICHD E-009-2021-0-PCT-02 THERAPEUTICS AGAINST PATHOGENIC CORONAVIRUSES PCT PCT PCT/US2021/060122 Expired
NIAID E-021-2021-0-PCT-02 NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF PCT PCT PCT/US2021/059941 Expired
NCATS E-234-2020-0-PCT-02 Small Molecule Inhibitors of Sars-Cov-2 Infections PCT PCT PCT/US2021/059910 Expired
NEI E-162-2016-0-HK-33 GENE THERAPY FOR RETINITIS PIGMENTOSA HK EP 42021042687.0 Pending
NIAID E-238-2020-0-US-01 EXPRESSION OF THE SPIKE S GLYCOPROTEIN OF SARS-COV-2 FROM AVIAN PARAMYXOVIRUS TYPE 3 (APMV3) US 63/280,884 Abandoned
NCATS E-010-2022-0-PCT-02 Protein And Lipid Therapeutic Targets PCT PCT PCT/US2021/059641 Expired
NCATS E-010-2022-0-US-02 Protein And Lipid Therapeutic Targets US National Stage 18/037,406 Pending
NCI E-109-2016-0-US-14 TARGETED CANCER THERAPY US DIV 17/528,827 Abandoned
NCI E-059-2013-0-HK-23 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor HK EP 42021042576.5 Pending
NLM E-107-2010-2-US-35 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 17/528,492 Abandoned
NIAID E-203-2020-0-KR-10 COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY KR National Stage 10-2021-7037335 Pending
NIAID E-023-2022-0-US-01 NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE US 63/279,675 Abandoned
NICHD E-209-2021-0-US-03 Kits And Methods To Distinguish False Labor And True Labor US DIV 17/525,717 11906528 Issued PDF
NICHD E-010-2021-0-PCT-02 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN PCT PCT PCT/US2021/059109 Expired
NIAID E-171-2021-0-US-01 SARS-COV-2 SPIKE FUSED TO HEPATITIS B SURFACE ANTIGEN US 63/278,956 Abandoned
NCATS E-098-2019-0-US-03 A SCALABLE SYNTHESIS OF DUAL-TARGET INHIBITOR OF CANNABINOID-1 RECEPTOR AND INDUCIBLE NITRIC OXIDE SYNTHASE US National Stage 17/610,537 12286405 Issued PDF